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Summary 
During feeding by infected mosquitoes, malaria sporozoites are injected into the host's bloodstream 
and enter hepatocytes within minutes. The remarkable target cell specificity of this parasite may 
be explained by the presence of receptors for the region II-plus of the circumsporozoite protein 
(CS) on the basolateral domain of the plasma membrane of hepatocytes. We have now identified 
these receptors as heparan sulfate proteoglycans (HSPG).  The binding of CS to the receptors 
is abolished by heparitinase treatment,  indicating that the recognition of region II-plus is via 
the glycosaminoglycan chains. We have purified and partially characterized the CS-binding HSPGs 
from HepG2 cells.  They have a molecular weight of 400,000-700,000,  are tightly associated 
with the plasma membrane, and are released from the cell surface by very mild trypsinization, 
a property which the CS receptors share with the syndecan family of proteoglycans. 
p revious observations indicate that a hepatocyte ligand for 
malaria sporozoites is contained in the COOH terminus of 
the circumsporozoite protein (CS) 1 (1, 2). This ligand is evo- 
lutionarily conserved among the CS of all malaria parasites. 
Here  we  designate  the conserved motif as region  II-plus 
(EWXXCXVTCGXGXXXRXK/R)  because it encompasses 
part of the previously defined region II (3), and because rec- 
ognition by the liver receptor requires the presence of the 
cluster of positively charged amino acids RXK/R  at the 3' 
end (Sinnis, P., B. Chair,  P. Clavijo, and V. Nussenzweig, 
manuscript in preparation).  Synthetic peptides representing 
portions of this sequence specifically inhibit host cell invasion 
by sporozoites, and binding of CS to its liver receptor (2). 
The nature of the sporozoite hepatocyte receptors is un- 
known, but several lines of evidence suggest that they are 
sulfated molecules. Sporozoites of Plasmodium  berghei bind 
specifically to sulfatide (4). CS has binding affinity for sulfa- 
tide, and for other sulfated macromolecules, such as heparin, 
fucoidan, and dextran sulfate (1, 4). CHO cells defective in 
genes affecting xylosyl-transferase and glycosaminoglycan bio- 
synthesis bind CS less effectively than the parental cells (4). 
Abbreviations used in this paper: CS, circumsporozoite  protein;  HSPG, 
heparan  sulfate  proteoglycan;  PI-PLC,  phosyhatidylinositol-specific 
phospholipase C. 
Moreover, thrombospondin, properdin, and other proteins 
that bind sulfatide contain the region II-plus motif (5-9). 
For these reasons, in the experiments to be described, we 
have attempted to reveal specific interactions between sulfated, 
biosynthetically labeled hepatocyte molecules and recombinant 
CS constructs. 
Materials and Methods 
Materials.  For the coimmunoprecipitation studies, we used ei- 
ther rat  (Brown Norway) liver, kidney tissue,  or HepG2 cells 
(HB8065;  American Type Culture Collection, Rockville,  MD) 
metabolically  labeled  with  carrier-free  Na23SSO, (Amersham 
Corp.,  Arlington  Heights,  IL)  or  with  [3SS]methionine and 
[3SS]cysteine (Tran3SS-label; ICN, Costa Mesa, CA). As ligands for 
the putative receptors, we used four recombinant Plasmodium  fat- 
ciparum CS proteins (2). Two of them are Escherichia coli derived 
(F. Hoffmann-La Roche Ltd.): CS27IVC, which contains region 
I, region II-plus, and a full representation  of the repeat domain; 
and CSFZ (Cys), which is identical to CS27IVC except that it con- 
tains only a single copy of the repetitive sequence NANP. The other 
two recombinants,  Falc-1 and Falc-2, are yeast derived and were 
kindly provided by Dr. I. Bathurst (Chiton Corporation, Emeryville, 
CA). Both Falc-1 and Falc-2 contain region I and the repeat do- 
main, but only Falc-2 contains region II-plus. The HepG2 binding 
assays were performed in tissue culture plates (Removawell; Dy- 
natech Laboratories, Chantilly, VA). For the immunoelectron mi- 
crocopy studies, glutaraldehyde (grade I; Sigma Immunochemicals, 
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NY); Lowicryl K4M and London Resin Co. (LR) White (Poly- 
sciences Inc., Warrington, PA) and protein A gold 15 nm (PAG15; 
Amersham Corp.) were used. For proteoglycan purification, G-25 
columns (PD-10; Pharmacia Fine Chemicals,  Piscataway, NJ) and 
Centricon-10  units  (Amicon,  Beverly,  MA)  were used.  Other 
reagents  were Ham's F-12 medium  (Sigma  Immunochemicals); 
methionine-free DMEM (Gibco, Grand Island, NY); the mAb 2A10 
(10) detecting the repeat domain ofP.fakit, arum CS; prefixed Staph- 
ylococcus aureus cells (S. aureus cells; Pansorbin;  Calbiochem-Nova- 
biochem Corp., La Jolla, CA); heparinase II (Sigma Immunochem- 
icals) and heparitinase (ICN; this enzyme does not degrade heparin), 
chondroitinase ABC  (Boehringer Mannheim,  Indianapolis,  IN; 
ICN), pronase (Boehringer Mannheim), heparin and chondroitin 
sulfate (both from Sigma Immunochemicals);  and phosphatidylino- 
sitol-specific phospholipase C  (PI-PLC; Boehringer Mannheim). 
Immunoelectron Microsco~.  Normal rat kidney tissue was fixed 
with 4% paraformaldehyde and 1% glutaraldehyde in PBS and em- 
bedded in LR White. Normal human liver was fixed similarly and 
embedded in Lowicryl K4M (2). Ultrathin sections were sequen- 
tially labeled with 10-50/~g/ml CS27IVC, 15/~g/ml mAb 2A10, 
and a 1:30 dilution of PAG15. Before immunolabeling, part of the 
sections were incubated for 120 min at 37~  with heparitinase or 
chondroitinase ABC (both from ICN) using concentrations of 20 
and 2 U/ml, respectively. Control specimens were incubated only 
with the gold markers or with mAb 2A10 and PAG15. 
Biosynthetic  Labeling.  Rats received two intraperitoneal injec- 
tions of 1 mCi carrier-free Na23sSO4, 24 and 12 h before they were 
euthanized. The livers and kidneys were chilled on ice, minced and 
homogenized in lysis buffer A (1% Triton X-100, 100 mM NaC1, 
50 mM Tris-HC1,  pH 7.2, 1% BSA; [Sigma Immunochemicals] 
containing 1 mM PMSF, 5/~g/ml each ofleupeptin, pepstatin, and 
antipain [all from Boehringer Mannheim] as protease inhibitors). 
After shaking for 2 h, the lysates were centrifuged at 16,000 g for 
30 rain. The supernatants were then used for coimmunoprecipita- 
tion with the CS recombinant proteins. 
Semiconfluent HepG2 cell monolayers were incubated with 100 
#Ci/well  Na23SSO4 in  Ham's  F-12 medium  supplemented with 
1-2% FCS equilibrated with PBS by Sephadex G-25 passage. The 
incubation was performed in 6-well plates  (Costar Corp., Cam- 
bridge, MA) for 6 h. After washing with PBS, the cells were scraped 
off the plate,  and treated with lysis buffer A for 30 min on ice. 
Supernatants for coimmunoprecipitation were obtained by spin- 
ning the lysates for 30 min at  16,000 g. 
A separate  sample of the cells was metabolically labeled with 
100  #Ci/well  [3SS]methionine  and  [3ss]cysteine  for  3  h  in 
methionine-free MEM containing 1% FCS equilibrated in PBS by 
Sephadex G-25 passage. 
Release of Proteoglycans  frora the Surface of nepG2 Cells.  Adherent 
HepG2  cells  labeled  with  Na23sso4  as  described  above  were 
washed three times with cold PBS, and then incubated for 5 min 
at 4~  with PBS containing 0, 2.5, 5, 10, 20, or 40/~g/ml trypsin 
(type XIII; Sigma Immunochemicals). The supernatants were re- 
moved  and  200  /~g/ml  soybean  trypsin  inhibitor  (Sigma  Im- 
munochemicals) was  added.  The trypsin-treated cells were then 
scraped off in PBS/BSA and extracts were prepared in lysis buffer 
A  as above. 
Separate samples of HepG2 cells labeled with sulfate were treated 
with 0, 31.25, 62.5, 125, 250, or 500/~g/ml heparin in medium 
for 10 min at 25~  or incubated with 0, 6.25, 12.5, 25, 50, and 
100 U/ml or PI-PLC for 60 min at 37~  The supernatants of the 
treated cells were analyzed by SDS-PAGE and by coprecipitation 
with the CS. Before coimmunoprecipitation with the recombinant 
CS proteins, the supernatants were mixed with 1:5 vol of lysis buffer 
A. The cell pellets were scraped off and lysed with buffer A as above. 
CS/Proteoglycan  Coimmunoprecipitation.  All extracts and super- 
natants were first precleared with normal rabbit serum and S. aureus 
cells. Then, 32/~g/ml of CSFZ (Cys) or 64/~g/ml of CS27IVC, 
Falc-2, or Falc-1 were added for 30 rain, followed by 10.8/~g/ml 
mAb 2A10 for 30 min, and 1% S. aureus cells (final concentrations). 
The suspensions were shaken for 1-5 h at 4~  The S. aureus cells 
were washed three times with the lysis buffer A, two times with 
lysis buffer B (10 mM Tris-HC1, pH 7.2, containing 100 mM NaC1 
and 0.5% NP-40), one time with 50 mM Tris-HC1, pH 7.2, and 
processed in this buffer for electrophoresis under reducing and non- 
reducing conditions. 
Samples of the immunoprecipitations were incubated with: 0.1 
U/ml heparitinase (ICN) in 50 mM Tris-HC1, pH 7.0, containing 
0.1% BSA; 1 U/ml chondroitinase ABC (ICN) in 50 mM Tris- 
HC1, pH 8.0, containing 0.1% BSA and 50 mM sodium acetate 
for 3 h at 37~  in the presence of protease inhibitors; or 100/zg/ml 
pronase for 1 h at 37~  After this treatment, the S. aureus cells 
were washed and processed  as above. 
SDS-PAGE.  3sSO4-1abeled  immunoprecipitates  were examined 
on either 5% or 3-20%  gradient polyacrylamide gels (11). The 
gels were fixed with 10% glacial acid and 30% methanol, impreg- 
nated for 30 rain in 1 M salicylic acid, dried, and exposed to Kodak 
X-Omat AR film at  -70~ 
Purification of HepG2  Cell Proteoglycans.  Trypsin-released  and 
3sso4-labeled proteoglycans were equilibrated in 50 mM Tris-HC1, 
pH 6.5 by passage in a Sephadex G-25 column, and concentrated 
by Centricon-10 centrifugation. Urea (Boehringer Mannheim) was 
added to a final concentration of 7 M, and the sample  subjected 
to anion exchange chromatography in a Mono-Q column using 
a FPLC apparatus  (Pharmacia  Fine Chemicals).  Elution was per- 
formed with 50 ml of a 0-2 M NaC1 gradient in 50 mM Tris-HC1, 
pH 6.5, containing 7 M urea.  1-ml fractions were collected and 
radioactivity counted in  20-/~1 aliquots.  Positive  fractions were 
pooled, equilibrated in 50 mM Tris-HC1, pH 7.2, and 7 M urea, 
and concentrated as above. A 200-~1 sample (22,500 cpm) was sub- 
jected to a Superose 6 column and eluted with 50 mM Tris-HC1, 
pH 6.5, and 7 M urea. Fractions (0.5 ml) were collected, and the 
cpm were counted in 20-/~1 aliquots.  Thyroglobulin (669  kD), 
apoferritin  (443  kD),  /3-amylase  (200  kD),  and  alcohol  de- 
hydrogenase (150 kD) were used as molecular weight markers (all 
from Sigma Immunochemicals). The combined positive fractions 
from three column runs were pooled and concentrated to a final 
volume of I ml. Part of this preparation was subjected  to hydrol- 
ysis and amino acid and amino sugar analysis  by Dr. S. Mische (Rock- 
efeller University, New York). For amino acid analysis, the hydrol- 
ysis was with 6 N HC1,  110~  22 h, and for amino sugars, 4 N 
HC1,  at 100~  for 7 h. Analysis was performed using Maxima 
software, a model 510 pump, and a model 490 detector. Novapak 
C8,  15-cm column was  used (all from Waters,  Bedford, MA). 
Inhibition  of Binding  of CS  to HepG2  Cells.  10  s HepG2 cells 
were deposited in 96-well Removawell tissue culture plates and al- 
lowed to grow overnight in MEM (Gibco) containing 10% FCS, 
1 mM r-glutamine (all from Gibco), 3 mg/ml glucose (Sigma Im- 
munochemicals) and lx  nonessential amino acids (Gibco). The 
HepG2 cells were fixed with 4% paraformaldehyde in TBS (50 mM 
Tris-HC1, pH 7.5, 137 mM NaC1, 2 mM KC1), washed three times 
with TBS, and stored at 4~  in BSA/TBS until use. CSFZ (Cys) 
at 5/zg/ml was incubated with increasing amounts of the presumed 
inhibitors at 37~  for 15 min. 50 t~l of these mixtures were added 
to the cells, incubated for 1 h at 37~  washed three times with 
TBS/0.05% Tween, and then sequentially incubated with 50/~1 
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for 30 rain at 37~  and 1:50 dilution  of goat anti-mouse IgG 
conjugated to alkaline phosphatase (Boehringer Mannheim) for 30 
rain. Bound enzyme was revealed by the addition of the fluores- 
cent  substrate,  4-methylumbelliferyl-phosphate  (Sigma  Im- 
munochemicals) in 100 mM Tris-HC1, pH 9.5, 100 mM NaC1, 
and 5 mM MgC12. After 15 rain, the fluorescence was measured 
in a plate reader (Fluoroskan II; ICN). 
In some experiments, the HepG2 calls were treated with either 
heparitinase (Sigma Immunochemicals) or chondroitinase ABC 
(ICN) before incubation with the CS. Heparitinase treatment was 
performed in 0.05 M acetate buffer, pH 6.0, containing 1 mg/ml 
BSA and I mM PMSF, and 5/~g/ml leupeptin and pepstatin. Cells 
were treated for 3 h at 37~  and then washed three times with 
TBS before protein was added. Chondroitinase ABC treatment was 
performed overnight at 37"C in 0.1 M Tris/HC1, pH 8.0, 0.03 M 
sodium acetate, and 0.1% BSA, and washed three times with TBS. 
Enzyme-treated  cells were then incubated with CS as outlined above. 
Results 
Heparitinase Digests the Plasma Membrane Receptors for 
CS.  To explore the possibility that the hepatocyte plasma 
membrane molecules that bind CS are proteoglycans, we in- 
cubated  human liver  sections  with  heparitinase  or  chon- 
droitinase ABC for 2 h at 37~  before immunolabding with 
recombinant C8.  The previously described, patchy pattern 
of CS-labeled hepatocyte microviili within the space of Disse 
(2), was still  present in the chondroitinase-treated sections 
(Fig. 1 a). However, heparitinase treatment abolished the Disse 
staining, and left only a faint labding of the hepatocyte lyso- 
somes (Fig.  1 b). 
As shown previously, CS binds to paraformaldehyde-fixed 
HepG2 ceils in a dose-dependent and saturable manner (2). 
The experiment illustrated in Fig. 2 shows that the CS binding 
to HepG2 cells is inhibited by heparin, heparan sulfate, dex- 
tran sulfate, and fucoidan, but not by chondroitin sulfate and 
dextran. In other experiments, the fixed HepG2 ceils were 
treated with different concentrations of heparitinase or chon- 
droitinase ABC, and then incubated with CS. As shown in 
Fig. 3, heparitinase~reatment prevented CS binding, whereas 
chondroitinase ABC treatment had no effect. 
CS Binds to Kidney Tubular Epithelia and Basement Mem- 
branes and to Mast Cell Granules.  We previously reported that 
recombinant CS does not bind to sections of several organs, 
including  spleen,  brain,  heart,  and  lung,  although  pro- 
teoglycans are present in all these organs. We have now ex- 
tended these studies, and detected a highly selective CS staining 
in mast cell granules and in the rat kidney, in a pattern con- 
sistent with proteoglycan involvement. In the kidney, CS binds 
specifically  to the basement membranes of the glomerular 
Bowman capsule,  proximal tubules, Henle loop, distal and 
collecting tubules, but not to the glomerular basement mem- 
brane (Fig.  4, a and b). In addition,  there was labeling on 
the basolateral domain of the proximal tubular epithelia, 
whereas the apical microvilli and all the other kidney epithelia 
were negative. The proximal epithelia showed intracellular 
CS staining of the lysosomes. To verify that proteoglycans 
in these locations were involved in CS binding, we treated 
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the kidney sections either with heparitinase or with chon- 
droitinase ABC before CS staining as above.  Again, only 
heparitinase abolished the staining (data not shown). 
Connective tissue mast cell granules were also intensely 
labeled by the CS protein (Fig. 5). In this case, however, the 
staining was affected neither by previous incubation with 
heparitinase (which does not cleave heparin), nor by chon- 
droitinase ABC treatment. 
CS Binds to Heparan Sulfate Proteoglycans  (HSPGs).  In the 
next series of experiments we attempted to identify the CS 
receptors in rat liver, rat kidney, and HepG2 cells. Our ap- 
proach was to biosynthetically label the cellular proteoglycans 
with 35804, incubate ceLl extracts with recombinant CS, and 
immunoprecipitate the complexes with a mAb directed against 
the CS repeats. Fig. 6 demonstrates that in these various lo- 
cations the recombinant protein CSFZ (Cys) binds to sul- 
fated macromolecuhs migrating as a smear on top of the SDS- 
PAGE gel, in a pattern typical of proteoglycans. Identical results 
were obtained when two other CS recombinants containing 
region II-plus (CS27IVC and Falc-2) were used, except that 
the immunoprecipitation was less efficient. Negative results 
were obtained with recombinant Falc-1, which does not con- 
tain region II-plus. 
Several additional observations indicate that the sulfated 
macromolecules that bind CS are HSPGs. The high molec- 
ular weight bands on SDS-PAGE  disappear after treatment 
of the immunoprecipitated material with heparitinase, but 
chondroitinase has no effect. Digestion of the immunoprecipi- 
tates with pronase results in a significant decrease of the ap- 
parent molecular weight of the sulfated molecules, which now 
migrate as a broad 200,000-Mr band in SDS-PAGE.  Also, 
the addition of 100/~g/ml of heparin to the lysates inhibits 
the immunoprecipitation reaction, presumably by competing 
with the labeled proteoglycans for CS (Fig.  7). 
The Nature of Membrane Attachment of the CS  Cellular 
Receptors.  HepG2  cells metabolically labeled with 35804, 
were incubated with increasing concentrations of trypsin for 
5 rain at 4~  In a dose-dependent manner, labeled mole- 
cules were released from the cell surface. A plateau was reached 
at 20/~g/ml of trypsin, when 50% of the total incorporated 
label was released.  Regardless of the trypsin concentration, 
about 80%  of the released counts were coimmunopredpi- 
tated with the CS recombinant CSFZ (Cys) (Fig. 8). Coim- 
munoprecipitation  of  the  trypsin-released  receptor  with 
CS27IVC and Falc-2 was less efficient, reflecting perhaps the 
degree and/or type of aggregate formation in the different 
recombinants (2). Neverthdess, all region II-plus containing 
CS recombinants bound sulfated molecules which migrated 
as smears on top of SDS-PAGE  gels (Fig.  9). 
From the total HepG2 cell extracts before trypsin treat- 
ment, and from those after trypsin treatment, 54 and 37% 
of the counts, respectively, were coimmunoprecipitated by 
CSFZ  (data  not  shown).  The  trypsin-insensitive,  im- 
munoprecipitable counts most likely represent HSPGs which 
are either intracellular or are associated with the plasma mem- 
brane in areas of the cells that are attached to the plastic and 
are inaccessible to trypsin. On SDS-PAGE gds, both cell as- 
sociated, and trypsin-released molecules ran similarly as high Figure  1.  CS receptors are heparitinase  sensitiv::. Electron  micrographs  of Lowicryl K4M-embedded  human liver labeled with CS27IVC,  followed 
by mAb 2A10 and PAG15. (a) This section was treated  with 2 U/ml chondroitinase  ABC (ICN) for 2 h at 37~  before  the immunolabeling.  The 
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cells. Proteoglycans  were preincubated  with 5 #g/ml of CSFZ (Cys)  and 
then added  to paraformaldehyde-fixed  HepG2 cells. Binding  of CS to the 
HepG2 cells  was revealed  by mAb 2A10, followed  by anti-mouse  alkaline 
phosphatase-conjugated  IgG. Bound  enzyme  was revealed  by a fluores- 
cent substrate,  4-methylumbelliferyl-phosphate.  Each  point represents  the 
mean of triplicates. Percent inhibition was calculated  by comparison to 
CSFZ (Cys) preincubated in medium alone. 
Figure  3.  CS binding to HepG2 cells is inhibited  by treatment  of the 
cells  with  heparitinase,  but not with  chondroitinase  ABC. Paraformaldehyde- 
fixed HepG2 cells were preincubated  with varying  amounts  of enzyme, 
washed, and then incubated  with 5 #g/ml of CSFZ (Cys). CS binding 
was revealed  as described  in Fig. 2. Heparitinase  and chondroitinase  ABC 
were used at initial concentrations  of 5 and 1 U/ml, respectively.  Each 
point represents  the mean  of triplicates, and percent inhibition  was calcu- 
lated by comparison to cells that were not treated with enzyme. 
molecular weight smears on top of the gel, indicating that 
mild trypsinization of the HepG2 cells does not lead to ex- 
tensive degradation of the proteoglycan core proteins (com- 
pare patterns in Fig.  7 and in the inset of Fig.  10). 
To further analyze the mode of  association of  the CS receptor 
to the membrane of the 3sSO4-1abeled HepG2 cells, the cells 
were treated with 0-100 U/ml PI-PLC for 60 min at 37~ 
or with 0-500 #g/ml heparin for 10 min at 25~  respec- 
tively. Neither treatment lead to the specific release of sulfate- 
labeled molecules. 
In an attempt to identify the core protein of the malarial 
protein HSPG receptor,  HepG2 cells were metabolically la- 
beled with [3SS]methionine and [3SS]cysteine  for 3 h. As re- 
vealed by SDS-PAGE,  the HepG2 cell extracts contained a 
very large number of radiolabeled proteins. However, after 
mild trypsinization as above (20 #g/ml, for 5 rain, at 4~ 
no counts were released in the supernatant above the back- 
ground (data not shown). As shown below, this observation 
greatly facilitated the isolation of the CS receptor from the 
supernatants. 
Purification and Properties of the CS Receptor  from HepG2 
Cell Membranes,  Subconfluent sulfate-labeled  HepG2 cells 
were incubated with 20 #g/ml trypsin as above, and the su- 
pernatants subjected to anion exchange chromatography on 
a Mono-Q column in buffers containing 7 M urea. The ra- 
diolabel was eluted from the column in a sharp peak (Fig. 
10), and about 80% of the counts in this peak were coim- 
munoprecipitated by CSFZ (Cys). Heparin, but not chon- 
droitin sulfate, inhibited coimmunoprecipitation. In addition, 
heparitinase  and  pronase,  but  not  chondroitinase  ABC, 
degraded the CS receptors (inset of Fig.  10). 
By molecular sieving  chromatography on a  Superose  6 
column, the purified HSPG eluted in a broad peak with an 
apparent molecular weight between 400,000 and 700,000 (Fig. 
11). The fractions in this peak were pooled and subjected to 
compositional analysis (Table 1). The results indicate the pres- 
ence of  large amounts of glucosamine, presumably originating 
from the heparan sulfate chains, and among the amino acids, 
a relatively high proportion of serine  and glycine. 
Discussion 
We have previously shown that hepatocytes bear on their 
plasma membranes specific receptors for region II-plus of the 
CS protein. Here we demonstrate that the hepatocyte receptors 
are HSPGs. This conclusion is based on observations made 
at the tissue,  cellular,  and molecular levels. The binding of 
CS  constructs  to  tissue  sections  and  to  HepG2  cells  is 
specifically inhibited by heparitinase treatment of the cells, 
and by the presence  of heparin in the incubation medium. 
In hepatocyte extracts, the CS receptors  are sulfated mole- 
cules of 400,000-700,000 daltons, which migrate as a smear 
on SDS polyacrylamide  gels and are digested by heparitinase. 
The size of the individual GAG chains, and of the core pro- 
tein, remain to be determined. After pronase digestion, the 
sulfated molecules are significantly reduced in size to about 
200,000  daltons, perhaps representing remnants of the core 
protein linked to multiple GAG chains. 
typical CS label on the space of Disse (D), on the lateral domain of the hepatocyte  plasma membrane (arrows),  and on lysosomes  (L) is unaltered. 
(b) This section  was treated  with 20 U/ml heparitinase  (ICN) under identical  conditions,  and subsequent CS staining  was not observed in the spaces 
of Disse (D). Only a faint label was left on the lysosomes  (L). (M) Mitochondrion;  (N) nucleus. Bars, 1 /zm. 
1291  Frevert  et al. Figure 4.  In the kidney, CS binds to the basolateral domains of proximal tubular epithelia, and to the basement membrane of the Bowman capsule. 
LIK White-embedded rat kidney sections labeled with CS271VC, mAb 2A10, and PAG15. (a) In the glomerulus,  the CS binding is restricted to the 
basement membrane  of the Bowman capsule, predominandy  to the laminae rarae (arrowheads). The giomerular basement membrane  below the fenestrated 
1292  Malaria CS Protein Binds to Proteoglycan Figure 5.  CS binds to connective tissue mast cell granules. Electron 
micrograph of an LR-White-embedded mast cell labeled with CS27IVC, 
mAb 2A10, and PAG15. The intracellular granules are intensely stained. 
Bar,  1 /~m. 
Figure 7.  Susceptibility of the CS receptor to heparitinase and pronase 
treatments.  Inhibition by heparin of the binding of the CS receptor to 
CSFZ(Cys). Coimmunoprecipitation of the CS receptor by CSFZ(Cys) 
was prevented by previous addition of 100 #g/ml heparin to 3sSO4-1abeled 
HepG2 cell extracts (control lane), whereas the same concentration ofchon- 
droitin sulfate had no effect. Digestion of the proteoglycans by 100/~g/ml 
pronase for 1 h at 37~  after coimmunoprecipitation,  results in a shift 
of the labeled smear to about 200 kD. Treatment of the immunoprecipi- 
tated material with 0.1 U/ml heparitinase for 3 h at 37~  led to complete 
degradation of the high molecular weight smear, whereas 1 U/ml chon- 
droitinase ABC had no effect. 
Figure 6.  CS binds to sulfate-labeled molecules with high molecular 
weight in extracts of liver, HepG2 cells, and kidney. Extracts of  cells meta- 
bolically labeled with 3sSO4 were incubated for 30 rain at 4~  with 32 
/~g/ml of recombinant CSFZ (Cys) or 64/~g/ml Falc-1, and immunopre- 
cipitated with mAb 2A10 and S. aureus cells. From the total liver lysate, 
CSFZ (Cys) coimmunoprecipitates sulfated molecules migrating as a smear 
on top of the SDS-PAGE.  Immunoprecipitation  with Falc-1 was negative. 
The SDS-PAGE patterns  of the total lysate of HepG2 cells, and of the 
Biosynthetically labeled, sulfated molecules are rapidly re- 
moved from the surface membrane of HepG2 cells by low 
concentrations of trypsin, and more than 80% of the labeled 
released molecules are precipitated with the CS. The 3sso4- 
labeled molecules from the membrane of HepG2 cells were 
purified by two chromatographic steps. By molecular sieving 
chromatography in the presence of 7 M urea, their apparent 
molecular weight is between 400,000 and 700,000 daltons, 
and on a molar basis they contain 40% ghcosamine, the amino 
sugar found in  heparan  sulfate  GAG  chains.  The smaller 
amounts of galactosamine may be derived from O-linked 
oligosaccharides,  or from chondroitin sulfate GAG chains. 
The amino acid analysis, which reflects only the composi- 
molecules coimmunoprecipitated  with CSFZ (Cys) resemble the corre- 
sponding liver SDS-PAGE patterns.  In kidney lysates, CSFZ (Cys) selec- 
tively immunoprecipitates a band of slightly  lower molecular weight than 
the total kidney-sulfated molecules. 
capillary endothelium (arrows) is unstained.  (CL) Capillary lumen; (P) podocyte; (BS) Bowman space. (b) The epithelia of the distal tubule (DT) show 
CS label only on the laminae rarae of the basement membrane (BM). In contrast,  the epithelia of the proximal tubule (PT) are also stained on their 
basolateral domains and on lysosomes (L).  Nucleus.  Bars, 1 /xm. 
1293  Frevert et al. Figure  8.  Trypsin sensitivity of the CS receptors from the surface of 
HepG2 cells. Subconfluent  HepG2 cells were incubated with various con- 
centrations of trypsin for 5 min at 4~  Sulfate label is released in the 
supernatant in a dose-dependent manner,  and maximum release (50% of 
the total incorporated cpm) is reached at 20/~g/ml trypsin. Independent 
of the trypsin concentration, about 80%  of the released HSPG is coim- 
munoprecipitated by 32 #g/ml CSFZ (Cys) and 10.8/xg/ml mAb 2A10. 
Under the same conditions, Falc-1 is negative. 
tion of the trypsin-resistant  portion of the core protein,  is 
not informative, except that it reveals the presence of a high 
content of serine and glycine. GAGs are known to be assem- 
bled on serine residues of the core protein, frequently  within 
the amino acid sequence acidic-X-Ser-Gly-acidic (12, 13). 
Heparitinase  digestion or the presence of heparin in the 
incubation medium hinders CS binding to the receptor. The 
GAG chains are therefore involved in CS recognition, a con- 
clusion further supported by the observation that the inva- 
sion of hepatocytes by sporozoites in vitro is inhibited by 
heparin,  dextran sulfate, and fucoidan (2, 4). Nevertheless, 
a role for the core protein(s) in the interaction with the CS 
cannot be excluded. 
HSPGs are ubiquitous constituents of  mammalian cell sur- 
faces. They may behave as integral  membrane proteins,  or 
peripheral membrane proteins that can be released from the 
cell membrane by treatment with  heparin  or high  ionic 
strength (14-19). Both types of HSPGs have been reported 
to be present on the hepatocyte surface exposed to the space 
of Disse. A third possible mode of membrane attachment 
is through a PI anchor (20). However, this is unlikely to be 
the mode of attachment of the CS receptors, since in epithe- 
lial cells, PI-anchored molecules  are sorted to their apical surface 
(21), whereas CS receptors are restricted  to the basolateral 
cell membrane of hepatocytes. In fact, CS receptors are not 
cleaved from the membrane of HepG2 cells by PI-PLC, and 
are not eluted by treatment of the cells  with heparin. As shown 
in Fig. 8, most sulfate-labeled CS receptors are released from 
subconfluent HepG2 cells by very mild trypsinization.  These 
results indicate that the core protein of the HSPG is tightly 
attached to the membrane of HepG2 cells (and of hepato- 
cytes [2]), most likely through a hydrophobic peptide anchor. 
Figure  9.  Binding of various CS constructs to proteoglycans released 
from  the  surface  of HepG2  cells by 20  ~g/ml  trypsin. 35SO4-1abeled 
trypsin-released proteoglycan (total supernatant)  was precipitated by CSFZ 
(Cys), Falc-2, CS27IVC,  and Falc-1. All constructs containing region ll- 
plus coimmunoprecipitated sulfated molecules migrating as smears on top 
of SDS-PAGE gds. The high molecular weight of the immunoprecipi- 
tated material shows  that trypsin did not lead to extensive degradation 
of the CS receptors. 
Table  1.  Compositional  Analysis of the Purified Trypsin-released 
HepG2 Cell Proteoglycan 
Percent  Percent 
Component  molar  Component  molar 
Gal-NH2  5.2  Pro  4.4 
Glc-NH2  40.5  Tyr  0.7 
Asp or  Asn  2.3  Val  2.4 
Glu or  Gin  4.5  Met  1.2 
Set  8.7  Cys  0.0 
Gly  12.8  Ile  1.9 
His  0.3  Leu  3.4 
Arg  0.9  Phe  1.1 
Thr  3.4  Lys  1.6 
Ala  4.8 
Fractions  13-22  from  Fig.  10  (19,000  cpm,  derived from  7  x  107 
HepG2 cells) were pooled and subjected  to amino acid and hexosamine 
analysis. On the basis of the results of the amino acid analysis, the sam- 
ple contained 2.8 txg of the proteoglycan. 
1294  Malaria CS Protein Binds to Proteoglycan Figure  10.  Ion exchange chromatography of trypsin-released HepG2 cell proteoglycans.  Concentrated, trypsin-released (20 #g/ml, 5 min at 4~ 
proteoglycans from HepG2 cells were loaded onto a Pharmacia  Mono-Q column and eluted with a 0-2 M  NaCI gradient in the presence  of 7 M 
urea. Sulfate-labded proteoglycans were ehted as a single sharp peak at a NaC1 concentration of 0.6-0.8 M. Note that protein was not detectable 
in the labeled peak. 1-ml fractions were collected and counted. (Inset) CSFZ (Cys) (32/~g/ml) precipitates the purified proteoglycans as a high molecular 
weight smear (lane I). Heparin (lane 2), but not chondroitin sulfate (lane 3) inhibits the precipitation. Pronase  (lane 4),  and heparitinase (lane 5), 
but not chondroitinase ABC (lane 6), degrade the high molecular weight band. 
CS receptors share some properties with the syndecan family 
of HSPGs. Syndecans are a gene family of integral membrane 
proteins (22), which bear both heparan sulfate and chondroitin 
sulfate chains. They are mainly synthesized by epithelial cells, 
and like the CS receptor, many are targeted to the basolateral 
side of the cell membrane (23). The GAG composition varies 
in a cell-specific fashion, and can be modulated by cytokines 
(24). Another characteristic feature of syndecans is that they 
contain a single dibasic site immediately upstream of the an- 
chor sequence which is very sensitive to proteolysis  (25, 26). 
As shown here,  the CS receptors can be released from the 
membrane of HepG2 cells  by treatment  for 5 min at 4~ 
with 10-20 #g/ml of trypsin, and may contain chondroitin 
sulfate  GAG  chains.  Several matrix  proteins  are  syndecan 
ligands,  including thrombospondin, which shares region II- 
Figure  11.  Molecular sieving chromatography  of purified proteoglycans 
released by trypsin from HepG2 cells. The peak labeled fractions from 
the anion exchange chromatography were pooled (22,500 cpm) and loaded 
onto a Superose 6 column in 50 mM Tris buffer pH 6.5 containing 7 M 
urea.  The 3sSO4 labd duted in a broad peak between 400 and 700 kD. 
Thyroglobulin (669 kD), apoferritin (443 kD), B-amylase (200 kD), and 
alcohol dehydrogenase (150 kD) were used as molecular weight markers. 
Fractions (500/~1) were collected and counted. Fractions 13-22 were pooled 
and used for the analysis shown in Table 1. 
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al.  (27) demonstrated the coexpression and identical tissue 
localization of syndecan and thrombospondin during mu- 
fine embryonic development. Although these observations 
provide some support for the hypothesis that the CS receptors 
are syndecans, the known syndecans have much lower mo- 
lecular weights than the CS receptors (22,  26,  28,  29). 
Microorganisms may take advantage of the widespread dis- 
tribution  of proteoglycans on cell surfaces  to use them as 
ligands for the attachment phases of infection. In recent years, 
there have been several examples of the utilization by viruses 
(herpes simplex, bovine herpes, and pseudorabies), and bac- 
teria (S. aureus, Bordetella pertussis, Streptococcus F/ogenes) of 
the GAG chains of HSPG as cellular adhesion sites (30-35). 
Chlamydia trachomatis appears  to bear heparan sulfate GAGs 
on its  surface,  which serve  as a bridge to attach to GAG 
receptors on the host cell surface membrane (36).  Among 
the protozoa, Trypanosoma cruzi attachment and penetration 
of host cells involves a surface molecule that specifically recog- 
nizes HSPG (37). 
It is unlikely that sporozoites and these various microbes 
bind to identical GAG receptors.  Heparan sulfate consists 
mainly of repeating disaccharide units [GlcA-GlcNAc]n, where 
GlcA is glucuronic acid and GIcNAc is N-acetyl-ghcosamine 
(38). However, these saccharides undergo N-deacetylation and 
N-sulfation of the GlcNAc residues,  O-sulfation at various 
positions, and epimerization of GlcA to iduronic acid. These 
secondary modifications give rise to an enormous structural 
diversity throughout the length of each GAG chain. For ex- 
ample, a specific pentasaccharide in heparin binds with high 
affinity to antithrombin III (39),  a distinctive dermatan sul- 
fate hexasaccharide activates heparin co-factor II (40),  and a 
specific heparan sulfate oligosaccharide is recognized by basic 
fibroblast growth factor (41). There is, in addition, increasing 
evidence of ordered aggregation and supramolecular organi- 
zation of GAG chains in solution (42).  In fact,  the GAG 
receptors for CS need not be of high affinity; if they are abun- 
dant on the hepatocyte membrane, the overall binding ca- 
pacity for sporozoites within the liver will be very high. It 
is conceivable that the retained sporozoites subsequently as- 
sociate with high affinity to receptors for other regions of 
the CS, or for other sporozoite ligands. Such a dual receptor 
system involving initial low affinity GAG binding is required 
for fibroblast growth factor activity (43). 
Another consideration is that the biological properties of 
structurally identical GAG chains in different tissues may vary, 
depending on whether the GAG chains are accessible to specific 
ligands. For example, CS-binding HSPGs are found in the 
laminae rarae of the tubular basement membranes in  the 
kidney, and in mast cell granules which contain a high con- 
centration of heparin. Renal tubular epithelia are separated 
from the blood circulation by fenestrated endothelia, but the 
fenestrae are closed with a diaphragm (44).  Therefore, the 
kidney HSPGs cannot compete with the hepatocyte HSPGs 
for the circulating malaria sporozoites. Likewise, the intra- 
cellular mast cell granules are inaccessible to the sporozoites. 
The relationship between the structure of heparin, and of 
the GAG chains of the HSPGs of hepatocytes and kidney base- 
ment membranes is not known. The elucidation of these struc- 
tures should contribute to the understanding of the molec- 
ular basis of the recognition of region II-plus, and facilitate 
the rational development of inhibitors for possible use in the 
immunoprophylaxis of malaria. Of particular interest for drug 
development are heparin derivatives, some of which have been 
injected in humans without toxic effects. It will also be of 
interest to verify whether HSPGs analogous to the CS receptors 
also bind F-spondin  (45),  Uric-5 (46),  and other proteins 
bearing the region II-plus motif, and to determine the physi- 
ological significance of this interaction. 
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